[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-366312-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-366312-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","overcoming-multidrug-resistance-in-gastrointestinal-cancers-with-a-cdh17-targeted-adc-conjugated-to-a-dna-topoisomerase-inhibitor","Overcoming multidrug resistance in gastrointestinal cancers with a CDH17-targeted ADC conjugated to a DNA topoisomerase inhibitor","","Cadherin 17 (CDH17) is investigated as a target for gastrointestinal cancers that frequently develop multidrug resistance (MDR) and relapse. The study develops 7MW4911, a CDH17-targeted antibody-drug conjugate (ADC) delivering the topoisomerase inhibitor MF-6 via a cleavable linker. It shows CDH17-specific binding and potent in vitro cytotoxicity, strong tumor growth inhibition (71%–99%) in preclinical models including patient-derived xenografts with diverse mutations, and improved performance over MMAE- and Deruxtecan-based ADCs in MDR settings.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/overcoming-multidrug-resistance-in-gastrointestinal-cancers-with-a-cdh17-targeted-adc-conjugated-to-a-dna-topoisomerase-inhibitor/366312/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/overcoming-multidrug-resistance-in-gastrointestinal-cancers-with-a-cdh17-targeted-adc-conjugated-to-a-dna-topoisomerase-inhibitor/366312.png","ImageObject",300,407,{"name":42,"@type":43},"Cart","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-10","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",15,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is 7MW4911 in this study?","Question",{"text":63,"@type":64},"7MW4911 is a CDH17-targeted antibody-drug conjugate (ADC) that carries the topoisomerase inhibitor MF-6 linked through a cleavable linker designed to address MDR in gastrointestinal cancers.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does 7MW4911 perform against multidrug-resistant GI cancer models?",{"text":68,"@type":64},"In preclinical MDR models, 7MW4911 outperformed MMAE-based and Deruxtecan (DXd)-based ADCs and produced substantial tumor growth inhibition, supporting effectiveness against drug-resistant cancer phenotypes.",{"name":70,"@type":61,"acceptedAnswer":71},"What safety and tolerability evidence is reported?",{"text":72,"@type":64},"The study reports favorable pharmacokinetics and a highest non-severely toxic dose (HNSTD) exceeding 20 mg/kg in cynomolgus monkeys, indicating a promising safety profile.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},366312,1790195340,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},18829141979164,"https://eur-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Article  \nOvercoming multidrug resistance in gastrointestinal cancers with a CDH17-targeted ADC conjugated toa DNA topoisomerase inhibitor  \nAuthors  \nRui Wang, Peng Fang, Xi Chen, ..., Datao Liu, Xiaoding Tan, Xun Gui  \nCorrespondence  \n[datao.liu@mabwell.com](datao.liu@mabwell.com) (D.L.),  \n[xiaoding.tan@mabwell.com](xiaoding.tan@mabwell.com) (X.T.),  \n[xun.gui@mabwell.com](xun.gui@mabwell.com) (X.G.)  \nIn brief  \nWang et al. develop 7MW4911, a CDH17-targeted ADC carrying a Top1 inhibitor MF-6 . 7MW4911 shows strong anti-tumor activity in diverse GI cancer models, including MDR tumors, and demonstrates a favorable safety profile in monkeys, supporting its potential for overcoming drug resistance and advancing to clinical development.  \n• 7MW4911 is a CDH17-targeted ADC with a Top1 inhibitor MF-6  \n• 7MW4911 shows strong efficacy in GI cancer models, including MDR tumors  \n• 7MW4911 demonstrates a favorable safety profile in NHP toxicology studies  \nWang et al., 2025, Cell Reports Medicine 6, 102213  \nJuly 15, 2025 © 2025 The Author(s) . Published by Elsevier Inc.  \n[https://doi.org/10.1016/j.xcrm.2025.102213](https://doi.org/10.1016/j.xcrm.2025.102213)  \nll  \nll  \nOPEN ACCESS  \nArticle  \nOvercoming multidrug resistance in gastrointestinal cancers with a CDH17-targeted ADC conjugated to a DNA topoisomerase inhibitor  \nRui Wang,1,5 Peng Fang,1,5 Xi Chen,1,2,5 Jiali Ji,1 Dongan Yu,1,3 Fei Mei,1,3 Zhenzhen Wang,1 Wei Zhou,1 Wenjing Peng,1 Rongjuan Wang,1,4 Jian Wang,1 Cuicui Guo,1 Hai Wu,1 Datao Liu,1,2,* Xiaoding Tan,1,3,* and Xun Gui1,6,*  \n1Mabwell (Shanghai) Bioscience Co. , Ltd. , Shanghai 201210, China  \n2National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun 130012, China  \n3Jiangsu Mabwell Health Pharmaceutical R&D Co. , Ltd. , Taizhou 225300, China  \n4Beijing Kohnoor Science & Technology Co. , Ltd. , Beijing 102206, China  \n5These authors contributed equally  \n6Lead contact  \n*Correspondence: [datao.liu@mabwell.com](datao.liu@mabwell.com) (D. L.), [xiaoding.tan@mabwell.com](xiaoding.tan@mabwell.com) (X.T.), [xun.gui@mabwell.com](xun.gui@mabwell.com) (X.G.) [https://doi.org/10.1016/j.xcrm.2025.102213](https://doi.org/10.1016/j.xcrm.2025.102213)  \nSUMMARY  \nCadherin 17 (CDH17) has emerged as a promising target for gastrointestinal (GI) cancers, which are often complicated by multidrug resistance (MDR) and recurrence. In this study, we developed 7MW4911, a CDH17-targeted antibody-drug conjugate (ADC) that incorporates a topoisomerase inhibitor MF-6 (Topi MF-6) payload linked via a cleavable linker, designed specifically to address MDR in GI cancers. 7MW4911 exhibited high specificity for CDH17-expressing cancer cells and potent cytotoxicity in vitro. In preclinical models, including patient-derived xenografts (PDXs) with distinct mutations, 7MW4911 achieved tumor growth inhibition ranging from 71% to 99% . Remarkably, 7MW4911 outperformed monomethyl auristatin E (MMAE)-based and Deruxtecan (DXd)-based ADCs in MDR models, highlighting its effectiveness against drug-resistant cancer phenotypes. Additionally, 7MW4911 showed favorable pharmacokinetics and a highest non-severely toxic dose (HNSTD) exceeding 20 mg/kg in cynomolgus monkeys, underscoring its promising safety profile. Together, these findings position 7MW4911 as a promising ADC candidate capable of enhancing therapeutic outcomes in GI cancers.  \nINTRODUCTION  \nGastrointestinal (GI) cancers, including liver, gastric, pancreatic, neuroendocrine tumor (NET), and, the most prevalent, colorectal cancers, are among the leading causes of cancer-related mortality globally. According to the International Agency for Research on Cancer (IARC) GLOBOCAN statistics, these cancers account for approximately 24.6% of all cancer diagnoses and 34.2% of cancer deaths.1 Globally, colorectal cancer (CRC) ranks third in overall cancer incidence and second in cancer-related mortality, while pancreatic cancer, though less common, had the hig","cbCaijrgZ5y7YnZm","https://ap.wps.com/l/cbCaijrgZ5y7YnZm","pdf",27507509,26,"English","# Summary\n# Introduction","[{\"question\":\"What is 7MW4911 in this study?\",\"answer\":\"7MW4911 is a CDH17-targeted antibody-drug conjugate (ADC) that carries the topoisomerase inhibitor MF-6 linked through a cleavable linker designed to address MDR in gastrointestinal cancers.\"},{\"question\":\"How does 7MW4911 perform against multidrug-resistant GI cancer models?\",\"answer\":\"In preclinical MDR models, 7MW4911 outperformed MMAE-based and Deruxtecan (DXd)-based ADCs and produced substantial tumor growth inhibition, supporting effectiveness against drug-resistant cancer phenotypes.\"},{\"question\":\"What safety and tolerability evidence is reported?\",\"answer\":\"The study reports favorable pharmacokinetics and a highest non-severely toxic dose (HNSTD) exceeding 20 mg/kg in cynomolgus monkeys, indicating a promising safety profile.\"}]","Overcoming multidrug resistance in gastrointestinal cancers with a CDH17-targeted ADC conjugated to a DNA topoisomerase inhibitor | PDF",1790164736,66,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/13ecf1a2fd9cd30d34381c7558c1afc6.webp",983,1276,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/57ae344f01a84bf8fd0a1d18ee066689.webp",982,1275,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/83e70f10473d074d49e0eb0b6c845b14.webp",981,1273,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/365225350b181f0cfc1ac517674797bf.webp",980,1272]